Most sermorelin telehealth visits run through a form and a short video call, not a physical exam. That is not automatically a problem — a lot of prescription medicine works this way now. But it puts the burden of asking good questions on you, before you pay, not after. These are the ones worth asking, and what a non-answer sounds like.
“What dose, in micrograms, will I actually be prescribed?”
This is the single most important question, and the one intake forms are least likely to answer up front. The only placebo-controlled adult trial of sermorelin used 10 micrograms per kilogram, nightly [1]. See how that trial dose translates by body weight against what gets marketed. Commercial protocols commonly advertise 200 to 300 micrograms, flat, regardless of weight — above anything tested in a published adult study.
Nobody is telling you which number is right; no trial has answered that. The point is narrower: “the standard protocol” is not an answer to “how many micrograms.” A prescriber who will not give you a number in writing before checkout is one to be wary of.
Bad answer: “We’ll determine that after your intake” — with no number given in writing until after you have paid.
“How will we know if it’s doing anything, and how often?”
IGF-1 bloodwork is the standard way to confirm sermorelin is stimulating growth hormone release at all. It is a biomarker, not proof the drug is doing anything you would notice day to day — the trial evidence on outcomes makes that gap explicit. A seller offering no lab monitoring is asking you to take their word for it twice: once that the drug is active, and again that whatever you are feeling is related to it.
Bad answer: “You’ll just feel it working” — with no labs offered or mentioned anywhere in the plan.
“What happens if I stop after two months?”
There is no published adult data on this. The only trial that tracked what happens after stopping sermorelin followed eight children, measuring growth rate — not the outcomes adults buy this drug for [2]. A prescriber who states with confidence exactly what will happen to your energy or body composition after you stop is offering an opinion as if it were settled science. Nobody has measured that in adults.
Bad answer: A confident, specific claim about what you will feel after stopping, delivered as fact.
“Which compounding pharmacy fills this, and can I see a certificate of analysis?”
Every sermorelin sold today is compounded. There is no current FDA-approved finished sermorelin product on the market, and the drug’s bulk-substance category under FDA’s compounding rules is listed as “Category 1, Under Evaluation” — not an approval. That makes the compounding pharmacy’s own quality control the thing standing between you and what is actually in the vial. A legitimate seller should be able to name the pharmacy, and ideally point you to a third-party certificate for the batch.
Bad answer: The pharmacy is not named anywhere on the site, and asking gets a vague answer about “licensed US pharmacies.”
“Is this FDA-approved?”
It is not, and the full regulatory picture is worth reading before you order. A prescriber who tells you it is should end the conversation right there. The honest version: a branded version, Geref, was approved decades ago and discontinued for business reasons, not safety ones. Everything sold today is compounded from bulk powder under a separate regulatory framework, and is not reviewed the way an approved drug is.
Bad answer: A yes, or vague language like “medical-grade” or “pharmaceutical strength” used as a stand-in for regulatory approval.
“What’s the total cost for three months, no coupon applied, and is any of it refundable?”
Sellers routinely show an intro-coupon or “starting at” number that does not match the standing rate. Get the real number before you commit, in writing, and ask specifically whether unused months are refundable if you stop. Compare that figure across the injections board or the oral formats before you decide, and see how sellers stack up side by side.
Bad answer: A number quoted verbally that is not the same as the number on the actual checkout page.
“Will you tell me about immune reactions, not just side effects?”
This one is narrower, but worth asking directly. In the one trial that tracked it closely, in children, 39 of 40 treated with a GHRH analog developed measurable antibodies against the drug [3]. That was not clinically consequential in that trial, and the antibodies mostly cleared within nine months of stopping. But it is a real, measurable immune response. That data is pediatric, not adult, and should not be over-applied — still, a prescriber who describes sermorelin as having no meaningful immune profile at all is not giving you the full picture. See the fuller side-effect record for what else has actually been measured.
Bad answer: “It’s completely safe, no real side effects” — delivered as a blanket statement, with no caveats.
Why this list matters more than the price
None of these questions are about whether sermorelin works. They are about whether the seller in front of you will be specific when specificity costs them a sale. A prescriber who answers all seven plainly, in writing, before you pay, has told you more about whether to trust them than any price on their homepage ever could.